企業概要
GoodRx Holdings, Inc. operates a price comparison platform designed to enable consumers to compare prescription drug prices and save on their medication purchases within the United States. The company functions within the Healthcare sector, specifically under the Health Information Services industry, providing information and tools that facilitate access to affordable pharmaceutical options. Its current market capitalization stands at $739.96M, supported by an annual revenue of $796.85M and an employee base of 697 individuals. These valuation and revenue figures indicate that GoodRx holds a significant position as a mid-cap enterprise in the digital health space, leveraging its operational scale to influence consumer access to drug pricing data.
財務健全性
The company reported a trailing twelve-month revenue of $796.85M, with a corresponding net income of $30.44M and an EBITDA of $122.31M. The substantial gap between the revenue of $796.85M and the net income of $30.44M reveals a cost structure where operating expenses and taxes consume approximately 96.2% of gross revenue before arriving at the bottom line. Free cash flow amounted to $81.94M, which provides the company with significant financial flexibility to fund operations, invest in technology infrastructure, or manage its capital structure without relying on external financing. Regarding profitability margins, the gross margin is 92.8%, reflecting high revenue recognition relative to the cost of goods sold, while the operating margin sits at 19.0%, indicating that roughly one-fifth of revenue remains after covering operating expenses. The profit margin is 3.8%, showing that the company retains a small portion of revenue as net earnings, a typical characteristic of high-growth or asset-light service models. On the balance sheet, cash holdings of $261.82M are compared against total debt of $542.81M, resulting in a debt-to-equity ratio of 88.08, which suggests a leveraged capital structure where liabilities significantly exceed equity. Despite the debt load, the current ratio of 2.61 indicates strong short-term liquidity, as current assets are more than double current liabilities, ensuring the ability to meet short-term obligations. Return on equity is 4.5% and return on assets is 4.8%, metrics that reveal management's effectiveness in generating returns relative to the shareholders' equity and the total asset base employed.
バリュエーション評価
The trailing twelve-month P/E ratio is 24.00, whereas the forward P/E is significantly lower at 5.88, implying that the market expects earnings to increase substantially in the coming years to justify the current valuation multiple. The price-to-book ratio is 1.20, indicating that the market values the company at a slight premium of 20% over its book value, suggesting confidence in the intangible assets and future cash flows beyond tangible net worth. Alternative valuation metrics such as the price-to-sales ratio of 0.93 and an EV/EBITDA of 8.35 suggest that the stock is priced conservatively relative to its sales and earnings power, particularly when considering the low forward multiple. The 52-week high is $5.81 and the 52-week low is $1.77, establishing a trading range where the stock has experienced significant volatility, though the specific current price position relative to this range requires real-time data not provided in the static facts. The beta value is 1.47, which means the stock is expected to exhibit 47% higher volatility than the broader market, reflecting the higher risk profile associated with the healthcare information services sector.
Growth & Income
Revenue growth year-over-year was -1.9%, while earnings growth year-over-year was -9.7%, indicating that earnings are contracting at a faster pace than revenue, which may point to rising cost pressures or a decline in profitability per unit of sales. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning it retains all of its earnings rather than distributing them to shareholders. Instead of providing income through dividends, the company reinvests its capital back into the business, likely focusing on platform expansion, technology development, or market acquisition to drive future growth. This growth and income profile highlights a capital-intensive reinvestment strategy typical of companies prioritizing expansion and market share consolidation over immediate shareholder returns.